Intercept Pharma (ICPT) to Present Data from Three PBC Studies Using OCA as Treatment
Tweet Send to a Friend
Intercept Pharma (Nasdaq: ICPT) announced results from three studies in primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC), that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
